PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
-6.92%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
121.05%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
121.15%
EPS growth above 1.5x TRVN's 25.31%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
115.11%
Diluted EPS growth above 1.5x TRVN's 25.31%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.25%
Share reduction more than 1.5x TRVN's 64.31%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
42.15%
Diluted share count expanding well above TRVN's 64.31%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-8.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-717224.10%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12351.82%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
45138.86%
Positive 10Y CAGR while TRVN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
41496.01%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
7331.25%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
8529.17%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
2357.47%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
2495.43%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
131.44%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-41.82%
We’re deleveraging while TRVN stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.65%
Our R&D shrinks while TRVN invests at 18.31%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
44.07%
SG&A growth well above TRVN's 22.51%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.